Extension of Time to File SOU

PTO- 1581

Approved for use through 03/31/2024. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1581

Approved for use through 03/31/2024. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

SOU Extension Request
(15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

MARK: CHOLESTOSOMES (see, http://uspto.report/TM/88141769/mark.png)
SERIAL NUMBER: 88141769

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Therasyn Sensors, Inc., having an address of
      100 Crosby Blvd
      Buffalo, New York 14226-3246
      United States
      Email: XXXX
Proposed: Therasyn Sensors, Inc., having an address of
      100 Crosby Blvd
      Buffalo, New York 14226-3246
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 11/05/2019.

For International Class 005:
Current identification: Pharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of lipids, containing and facilitating the delivery of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of cholesteryl ester, containing and facilitating the delivery of pharmaceuticals for use in the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non- alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; and vaccines and vaccinations to prevent or treat infectious diseases and cancer

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the third extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development ; market research ; manufacturing activities

Correspondence Information (current):
      R. Neil Sudol
      PRIMARY EMAIL FOR CORRESPONDENCE: rnsudol@cssiplaw.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): moconnell@cssiplaw.com; rnspatent@netzero.net

Correspondence Information (proposed):
      R. Neil Sudol
      PRIMARY EMAIL FOR CORRESPONDENCE: rnsudol@cssiplaw.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): moconnell@cssiplaw.com; rnspatent@netzero.net


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /R. Neil Sudol/      Date Signed: 04/26/2021
Signatory's Name: R. Neil Sudol
Signatory's Position: Attorney for applicant, member NY State bar
Signatory's Phone: 203-366-3560
Signature method: Signed directly within the form

PAYMENT: 88141769
PAYMENT DATE: 04/26/2021

Serial Number: 88141769
Internet Transmission Date: Mon Apr 26 14:09:27 ET 2021
TEAS Stamp: USPTO/ESU-XX.XXX.XXX.XXX-202104261409271
51526-88141769-78059fece72e122bce24229b7
07ac93f75317142198fe1747e75a2c922e6d222-
DA-09250791-20210426140722236545